Risultati per: Diagnosi precoce del tumore al pancreas in medicina generale

Il convegno “Per Amarla-Percorso e Rete Mammella Regione Lazio”

Nato in Italia e basato sul genoma, nel mirino il neuroblastoma

Passi avanti per i pazienti non operabili con la mutazione del gene Egfr

Morto a 92 anni per i postumi di un incidente a Forlì

Oncologi, ma attenzione alla corretta comunicazione dei dati scientifici

Introduction
Multiple automated insulin delivery (AID) systems have become commercially available following randomised controlled trials demonstrating benefits in people with type 1 diabetes (T1D). However, their real-world utility may be undermined by user-associated burdens, including the need to carbohydrate count and deliver manual insulin boluses. There is an important need for a ‘fully automated closed loop’ (FCL) AID system, without manual mealtime boluses. The (Closed Loop Open SourcE In Type 1 diabetes) trial is a randomised trial comparing an FCL AID system to the same system used as a hybrid closed loop (HCL) in people with T1D, in an outpatient setting over an extended time frame.

Methods and analysis
Randomised, open-label, parallel, non-inferiority trial comparing the Android Artificial Pancreas System (AAPS) AID algorithm used as FCL to the same algorithm used as HCL. Seventy-five participants aged 18–70 will be randomised (1:1) to one of two treatment arms for 12 weeks: (a) FCL—participants will be advised not to bolus for meals and (b) HCL—participants will use the AAPS AID algorithm as HCL with announced meals. The primary outcome is the percentage of time in target sensor glucose range (3.9–10.0 mmol/L). Secondary outcomes include other glycaemic metrics, safety, psychosocial factors, platform performance and user dietary factors. Twenty FCL arm participants will participate in a 4-week extension phase comparing glycaemic and dietary outcomes using NovoRapid (insulin aspart) to Fiasp (insulin aspart and niacinamide).

Ethics and dissemination
Approvals are by the Alfred Health Ethics Committee (615/22) (Australia) and Health and Disability Ethics Committees (2022 FULL 13832) (New Zealand). Each participant will provide written informed consent. Data protection and confidentiality will be ensured. Study results will be disseminated by publications, conferences and patient advocacy groups.

Trial registration numbers
ACTRN12622001400752 and ACTRN12622001401741.

Il colangiocarcinoma è una neoplasia in aumento ma poco conosciuta

Si occuperà dei piani di indirizzo e gestione dell’associazione

Ridurranno del 70% gli esami inutili

‘Ho avuto anche io la neoplasia. Parlo di cancro col sorriso’

+14% di diagnosi l’anno. Al via la nuova campagna d’informazione degli oncologi

Esperti, ‘fa guadagnare ai pazienti ulteriori mesi e anni di vita’

Studio Usa, essere fisicamente attivi ne diminuisce l’intensità

Miglioramento della sopravvivenza a 5 anni se il tumore è in fase precoce

Usa un trucco genetico. Studio apre a nuove cure

Grazie a nuove terapie la sopravvivenza è notevolmente migliorata